Literature DB >> 15861378

Inhibition of mitosis by glycopeptide dendrimer conjugates of colchicine.

David Lagnoux1, Tamis Darbre, M Lienhard Schmitz, Jean-Louis Reymond.   

Abstract

Glycopeptide dendrimers have been prepared bearing four or eight identical glycoside moieties at their surface (beta-glucose, alpha-galactose, alpha-N-acetyl-galactose, or lactose), natural amino acids within the branches (Ser, Thr, His, Asp, Glu, Leu, Val, Phe), 2,3-diaminopropionic acid as the branching unit, and a cysteine residue at the core. These dendrimers have been used as drug-delivery devices for colchicine. Colchicine was attached to the dendrimers at the cysteine thiol group through a disulfide or thioether linkage. The biological activities of the glycopeptide dendrimer conjugates were evaluated in HeLa tumor cells and non-transformed mouse embryonic fibroblasts (MEFs). The concentrations of glycopeptide dendrimer drug conjugates required to achieve inhibition of cell proliferation by interference with the tubulin system were found to be higher (IC50 > 1 microM) compared to the required colchicine concentration. On the other hand, the glycopeptide dendrimer conjugates inhibited the proliferation of HeLa cells 20-100 times more effectively than the proliferation of MEFs. In comparison, non-glycosylated dendrimers and colchicine itself showed a selectivity of 10-fold or less for HeLa cells.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15861378     DOI: 10.1002/chem.200401294

Source DB:  PubMed          Journal:  Chemistry        ISSN: 0947-6539            Impact factor:   5.236


  7 in total

1.  Peptide- and saccharide-conjugated dendrimers for targeted drug delivery: a concise review.

Authors:  Jie Liu; Warren D Gray; Michael E Davis; Ying Luo
Journal:  Interface Focus       Date:  2012-03-21       Impact factor: 3.906

2.  Design, Synthesis, and Antitumor Activity of 4-Halocolchicines and Their Pro-drugs Activated by Cathepsin B.

Authors:  Naoko Yasobu; Mariko Kitajima; Noriyuki Kogure; Yoshiyuki Shishido; Takeshi Matsuzaki; Masato Nagaoka; Hiromitsu Takayama
Journal:  ACS Med Chem Lett       Date:  2011-03-04       Impact factor: 4.345

3.  Synthesis and characterization of BODIPY-labeled colchicine.

Authors:  Leggy A Arnold; Patricia Ranaivo; R Kiplin Guy
Journal:  Bioorg Med Chem Lett       Date:  2008-07-20       Impact factor: 2.823

4.  A polymeric colchicinoid prodrug with reduced toxicity and improved efficacy for vascular disruption in cancer therapy.

Authors:  Bart J Crielaard; Steffen van der Wal; Twan Lammers; Huong Thu Le; Wim E Hennink; Raymond M Schiffelers; Gert Storm; Marcel Ham Fens
Journal:  Int J Nanomedicine       Date:  2011-11-02

5.  Can the Thiol/Disulfide Imbalance Be a Predictor of Colchicine Resistance in Familial Mediterranean Fever?

Authors:  Ahmet Omma; Sevinc Can Sandikci; Orhan Kücüksahin; Murat Alisik; Ozcan Erel
Journal:  J Korean Med Sci       Date:  2017-10       Impact factor: 2.153

6.  Evaluation of a 99mTc-tricine Vascular Disrupting Agent as an In-vivo Imaging in 4T1 Mouse Breast Tumor Model.

Authors:  Mostafa Erfani; Seyed Pezhman Shirmardi; Mohammad Shafiei
Journal:  Iran J Pharm Res       Date:  2017       Impact factor: 1.696

Review 7.  Dendrimers in drug delivery and targeting: Drug-dendrimer interactions and toxicity issues.

Authors:  Kanika Madaan; Sandeep Kumar; Neelam Poonia; Viney Lather; Deepti Pandita
Journal:  J Pharm Bioallied Sci       Date:  2014-07
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.